The U.S. Food and Drug Administration has issued a safety announcement that the risk of progressive multifocal leukoencephalopathy (PML) increases with the number of infusions received of Tysabri (natalizumab) (www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm).